Effect of sublingual soft gel of essential oil of Pistacia atlantica in asthma

Evaluation of the effect of sublingual soft gel containing Pistacia atlantica oleoresin essential oil on symptomatic and spirometric improvement of patients with moderate to severe asthma compared with standard treatment: A triple-blinded, randomized, placebo-controlled trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20100420003760N7

Enrollment

Registered

2023-04-17

Start date

2023-05-24

Completion date

Unknown

Last updated

2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma. Asthma

Interventions

Intervention 1: Intervention group1: The group receiving common treatment and 200 mg sublingual soft gel containing 40 mg of Pistacia atlantica oleoresin essential oil (Soft gel is made according to

Eligibility

Sex/Gender

All

Age

15 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients aged 15 years and older who referred to the asthma and allergy specialist's office with a diagnosis of moderate or severe allergic asthma

Exclusion criteria

Exclusion criteria: Having other respiratory diseases except asthma Pregnant and lactating women People with a history of drug allergy Taking anti-leukotriene drugs People who use supplements or other inhalation and non-inhalation drugs Having special diseases such as dialysis patients (hemophilia, thalassemia, and MS) and incurable (cystic fibrosis (CF), mucopolysaccharidosis (MPS), spinal muscular atrophy (SMA), metabolic diseases, and autism) lung cancer

Design outcomes

Primary

Measure	Time frame
The times of waking up with an asthma attack during the past week (zero to six according to the questionnaire). Timepoint: Before, and after intervention. Spirometry time 0 and 30. Method of measurement: Through Asthma Control Questionnaire and spirometry.;The severity of symptoms during the past week (zero to six according to the questionnaire). Timepoint: Before, and after intervention. Spirometry time 0 and 30. Method of measurement: Through Asthma Control Questionnaire and spirometry.;The amount of restriction in daily activities during the past week (zero to six according to the questionnaire). Timepoint: Before, and after intervention. Spirometry time 0 and 30. Method of measurement: Through Asthma Control Questionnaire and spirometry.;The severity of breath during the past week (zero to six according to the questionnaire). Timepoint: Before, and after intervention. Spirometry time 0 and 30. Method of measurement: Through Asthma Control Questionnaire and spirometry.;Wheezing during the past week (zero to six according to the questionnaire). Timepoint: Before, and after intervention. Spirometry time 0 and 30. Method of measurement: Through Asthma Control Questionnaire and spirometry.;The daily puffs of short-acting inhaled bronchodilators used during the past week (zero to six according to the questionnaire). Timepoint: Before, and after intervention. Spirometry time 0 and 30. Method of measurement: Through Asthma Control Questionnaire and spirometry.	—

Measure

Time frame

The times of waking up with an asthma attack during the past week (zero to six according to the questionnaire). Timepoint: Before, and after intervention. Spirometry time 0 and 30. Method of measurement: Through Asthma Control Questionnaire and spirometry.;The severity of symptoms during the past week (zero to six according to the questionnaire). Timepoint: Before, and after intervention. Spirometry time 0 and 30. Method of measurement: Through Asthma Control Questionnaire and spirometry.;The amount of restriction in daily activities during the past week (zero to six according to the questionnaire). Timepoint: Before, and after intervention. Spirometry time 0 and 30. Method of measurement: Through Asthma Control Questionnaire and spirometry.;The severity of breath during the past week (zero to six according to the questionnaire). Timepoint: Before, and after intervention. Spirometry time 0 and 30. Method of measurement: Through Asthma Control Questionnaire and spirometry.;Wheezing during the past week (zero to six according to the questionnaire). Timepoint: Before, and after intervention. Spirometry time 0 and 30. Method of measurement: Through Asthma Control Questionnaire and spirometry.;The daily puffs of short-acting inhaled bronchodilators used during the past week (zero to six according to the questionnaire). Timepoint: Before, and after intervention. Spirometry time 0 and 30. Method of measurement: Through Asthma Control Questionnaire and spirometry.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMarzieh Rashidipour

Khoram-Abad University of Medical Sciences

m_rashidi80@yahoo.com+98 66 3312 0172

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026